WBB Securities upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a buy rating to a strong-buy rating in a report published on Thursday, September 20th, Marketbeat reports.
“Mesoblast announced continued positive survival data for remestemcel-L (allogeneic cell therapy) in children with steroid refractory acute graft vs. host disease (aGvHD). The next step for the company is meeting with FDA to discuss BLA submission. The cell therapy is already approved in Japan (as TEMCELL HS Inj) for aGvHD, licensed to JCR Pharmaceuticals Co Ltd (TYO: 4552 – NR).”,” the firm’s analyst wrote.
Several other research firms also recently issued reports on ARCT. Zacks Investment Research upgraded Arcturus Therapeutics from a sell rating to a hold rating in a report on Tuesday, June 12th. LADENBURG THALM/SH SH upgraded Arcturus Therapeutics from a neutral rating to a buy rating in a report on Thursday, May 31st. Finally, ValuEngine upgraded Arcturus Therapeutics from a sell rating to a hold rating in a report on Wednesday, June 6th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Arcturus Therapeutics currently has an average rating of Buy and an average price target of $12.00.
Arcturus Therapeutics stock traded up $0.28 during trading on Thursday, reaching $7.00. 2,218 shares of the company were exchanged, compared to its average volume of 43,280. Arcturus Therapeutics has a 52-week low of $4.78 and a 52-week high of $15.19. The company has a market cap of $94.98 million, a price-to-earnings ratio of -1.98 and a beta of 1.26.
An institutional investor recently raised its position in Arcturus Therapeutics stock. ARK Investment Management LLC increased its stake in shares of Arcturus Therapeutics Ltd (NASDAQ:ARCT) by 61.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 533,773 shares of the biotechnology company’s stock after purchasing an additional 202,608 shares during the quarter. ARK Investment Management LLC owned 4.97% of Arcturus Therapeutics worth $4,526,000 at the end of the most recent quarter. 7.65% of the stock is owned by institutional investors.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.